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developed to evaluate the relative effectiveness between the NOACs and warfarin
for the primary efficacy endpoint of stroke or systemic embolism (SE) and primary
safety endpoint of major hemorrhage. Secondary endpoints included ischemic
stroke, hemorrhagic stroke, SE, myocardial infarction, intracranial hemorrhage,
gastrointestinal hemorrhage, cardiovascular-related mortality, and all-cause mor-
tality. A probability of best treatment was calculated for each antithrombotic agent
for the different outcomes. RESULTS: Dabigatran-150mg, rivaroxaban, and apixa-
ban showed significant relative risk (RR) reductions over warfarin for stroke or SE
(RR0.65, 0.78, 0.79, respectively). However, indirect comparisons did not reveal
significant differences between the individual NOACs. For the primary safety end-
point, dabigatran-110mg was significantly better than warfarin (RR0.81) and ri-
varoxaban (RR0.79) whereas apixaban showed significant reduction over warfa-
rin, dabigatran-150mg, and rivaroxaban (RR0.70, 0.75, 0.69, respectively).
Significant differences between the NOACs were also found for secondary end-
points of hemorrhagic stroke, intracranial hemorrhage, and gastrointestinal hem-
orrhage. However, no significant findings were observed for cardiovascular and
all-cause mortality. CONCLUSIONS:Overall, the NOACs showed varying levels and
areas of improvement over warfarin. The analyses identified dabigatran-150mg
and apixaban as the best option for the prevention of stroke or SE and major
hemorrhage, respectively.
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COMBINATIONS: NETWORK META-ANALYSES
Vieira MC1, Ellis AG1, Lowy A2, Deschaseaux C2, Jansen JP1
1MAPI Consultancy, Boston, MA, USA, 2Novartis Pharma AG, Basel, Switzerland
OBJECTIVES:To compare efficacy and tolerability of drug classes and combinations
for chronic heart failure (HF) based on evidence from randomised controlled trials
(RCTs) to populate an economic model with updated estimates. METHODS: A sys-
tematic literature review (2000-2011) identified 54 RCTs of angiotensin converting
enzyme inhibitors (ACEI), beta-blockers (BB), angiotensin II receptor blockers (ARB),
and aldosterone antagonists (AA). Efficacy and tolerability results of individual
studies were combined by network meta-analyses. RESULTS: Numbers of regi-
mens which could be compared varied, depending on the outcome considered. For
all-cause deaths and left-ventricular ejection fraction (LVEF), 10 regimens could be
included (ACEI; BB; ARB; BBACEI; ARBACEI; AAACEI; BBACE or ARB;
BBACEIARB; BBACEI or ARBAA; ACEI or ARB); for other outcomes, up to five
of these could not be included. All-cause deaths varied from 4 per 100 person-years
(95% Credible Interval: 1-12) for the combination of AA, BB and ACEI or ARB to 14 per
100 person-years (9-22) for ACEI. Hospitalisation rates varied from 74 hospital stays
per 100 patient-years (53-104) with the combination of BB and ACEI to 106 hospital
stays per 100 patient-years (63-181) with BB. Increase in LVEF was the highest for
the combination of ACEI, ARB and BB (8.44%; 4.24-12.96), followed by the combina-
tion of AA, ACEI or ARB, and BB (7.11%; 4.57-9.71). Withdrawal rates (all cause) were
higher for the combinations of ACEI and ARB (70 per 100 patient-years; 41-128) and
lower for the combination of ACEI, ARB and BB (0; 0-25). Withdrawals rates (due to
adverse events) showed similar results. CONCLUSIONS: Network meta-analyses
allow the estimation and comparisons of efficacy and tolerability of HF drug classes
and combinations. The ranking of treatments from best to worst varied across
outcomes, but an overall conclusion was that combinations were the most effica-
cious without being necessarily the least tolerable.
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OBJECTIVES: To assess the impact of real life statin utilization on the risk of first
non-fatal myocardial infarction (MI) METHODS: Case-control methodology using
the pharmacoepidemiological information system ’PGRx’. Data on comorbidities,
risk factors and medications were obtained from medical records and patient tele-
phone interviews. General practices (n371) and cardiology centres (n60) across
France were employed in the study. Cases were patients with the first MI 1
month before the date of recruitment (n2238). Controls were patients seen by a
general practitioner (GP) with no restriction as to the reasons of consultation
(n2238), matched to MI cases on gender, age, frequency of visits to a doctor, date
of recruitment and personal history of non-cardiovascular chronic disease. Statin
exposure was defined as any utilisation in the two-year prior to date of MI in cases
or recruitment date in controls. Adjusted odds ratios (OR) of the risk of first MI was
estimated by multiple conditional logistic regression models. Comparative effec-
tiveness and propensity to use of individual statin molecules were assessed.
RESULTS: The use of statins was associated with a lower MI risk (adjusted OR 0.67
[95% CI 0.56 - 0.79] for current use (within 2 months before the index date) and 0.73
[0.62 0.86] for any use within 24 months). Among individual statins, rosuvastatin
was associated with the lowest MI risk (adjusted OR 0.49 [0.35 - 0.68] for any use in
24 months preceding the index date) followed by simvastatin (0.62 [0.46 - 0.84]).
CONCLUSIONS: In this first major population-based observational study we repro-
duced the results observed in recent meta-analyses accounting for real life com-
pliance and population variability. The results could be of interest and applicable to
other industrialised countries as the observed risk reduction was constant across
MI risk levels.
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COLESEVELAM FOR THE TREATMENT OF HYPERLIPIDEMIA: A RETROSPECTIVE
‘REAL-WORLD’ ANALYSIS FROM AN INTEGRATED HEALTH SYSTEM
Romanelli R1, Leahy A1, Jukes T1, Ye X2, Luan A2, Ishisaka D1
1Sutter Health, San Francisco, CA, USA, 2Daiichi Sankyo, Parsippany, NJ, USA
OBJECTIVES: To examine effectiveness of Colesevelam in reducing low-density
lipoprotein cholesterol (LDL-C) among patients with hyperlipidemia (HL) in the
real-world setting. METHODS: In this retrospective study, patients with HL were
identified through electronic health records, who were 18 years old, and had an
initial order for colesevelam between Jan 2004 and Dec 2011, an LDL-C value within
3 months of the initial order date (baseline), and 12 months of LDL follow-up and
continuous colesevelam treatment. Outcome measures were LDL-C and the per-
cent of patients at the appropriate LDL-C goal based on NCEP ATP III guidelines.
Generalized estimating equation models were used to assess differences in LDL-C
outcome measures between baseline and 12-months follow-up, adjusting for co-
variates including statin and other medication use. A p-value0.05 was considered
statistically significant. Missing data were imputed by linear interpolation. Sensi-
tivity analysis with and without imputation was performed. RESULTS: A total of
468 patients met the predefined inclusion criteria and had a mean age of 63 years
old. Of these patients, 48.7% were females and 73.3% had prior statin use. Mean
change in LDL-C from baseline at 12 months was -11.4 mg/dL (p0.0001), a relative
decrease of 9.6%. The percent of patients at LDL-C goal at baseline was 42.3%, which
increased to 56.2% (p0.0001) at 12 months. CONCLUSIONS: Long-term, continu-
ous colesevelam treatment was associated with a significant reduction in LDL-C
and an increase in the percent of patients achieving LDL-C goal from baseline. This
is the first ‘real-world’ analysis demonstrating the benefits of colesevelam among
patients with HL in a community-based integrated health system. The LDL-C low-
ering results parallel findings from pivotal clinical trials.
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OBJECTIVES:Meta-epidemiological studies have shown that open-label trials were
potentially biased and, in average, overestimate treatment effect magnitude by
about 14% compared to double-blind trials. In network meta-analysis where the
two types of trials are present, this bias could influence indirect comparisons and
favor the less rigorous trials. The objective was to estimate the relative efficacy of
apixaban compared to other new anticoagulants (NOAC) in stroke and systemic
embolism prevention in atrial fibrillation (AF) using indirect comparison meta-
analysis and taking into account the bias of open-label trial such RELY (dabigatran).
METHODS: We performed a systematic literature review to identify all RCTs eval-
uating NOAC in AF. Adjusted indirect comparisons and bias correction were con-
ducted using methods derived from those described by Bucher et al. and Welton et
al., respectively. The magnitude of the bias induced in treatment effect estimation
by open-label studies was estimated using meta-epidemiological studies from Juni
et al. This bias correction was unnecessary for rivaroxaban results given that
ROCKET AF was double-blinded. RESULTS: No statistically significant difference in
the composite endpoint of stroke and systemic embolism was found between
apixaban versus dabigatran 150mg/d (odds-ratio: 1.03, 95%CI [0.75;1.42]), between
apixaban versus dabigatran 110mg/d (0.75 95%CI [0.55;1.02]), and between apixa-
ban versus rivaroxaban (0.90 95%CI [0.70;1.15]). For ischemic strokes, indirect com-
parisons for apixaban versus comparators were: 1.09 [0.75;1.58] versus dabigatran
150mg BID, 0.72 [0.51;1.04] versus dabigatran 110mg BID and 1.03 [0.75;1.42] versus
rivaroxaban. CONCLUSIONS: After correction for the potential bias of the phase 3
trial of dabigatran due to the open-label design, indirect comparisons of the apixa-
ban to dabigatran showed no significant difference in terms of stroke or systemic
embolism and ischemic stroke for the 2 doses. Further research on a AF specific
bias estimation should be undertaken to better understand the magnitude of the
possible effect size overestimation in RELY open-label study.
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OBJECTIVES: Cardiovascular diseases are the most frequent cause of morbidity
and mortality in many countries. That explains why medications for the treatment
of cardiovascular diseases are the most used group of drugs. The aim of this study
was to analyze the consumption of ACE inhibitors in Serbia during 2009 and 2010
year from pharmacotherapeutic and pharmacoeconomic point of view.METHODS:
The data about the use of ACE inhibitors were taken from the Agency for Drugs and
Medical Devices of the Serbia. RESULTS: During both analyzed years significant
part of consumption of ACE inhibitors was taken by more expensive drugs in Ser-
bia, as fosinopril, cilazapril and quinapril, though they have not been used in Nor-
way at all during that period. During 2009 year, fosinopril as a very expensive drug
took second, and during 2010 it took third place on the list of the total utilization of
monocomponent ACE inhibitors in Serbia. If the consumption of fosinopril in Ser-
bia was reduced to a minimum as in Norway, and if the patients were offered
enalapril instead, the savings in Serbia in 2009 would have been around
7.800.000,00 € only from this product. CONCLUSIONS: In Serbia in 2009 and 2010
year, ACE inhibitors and their fixed combination with diuretics are the most fre-
quently used drugs within the group of drugs which is used for cardiovascular
diseases treatment. The amount and structure of the utilized ACE inhibitors in
Serbia is different in a lot of ways from the amount and structure of the utilized ACE
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